Skip to main
AAPG
AAPG logo

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group has shown significant commercial growth, with olverembatinib achieving sales of RMB 217.4 million (approximately US$30.3 million) in the first half of 2025, reflecting a remarkable 93% year-over-year increase and cumulative sales surpassing US$100 million since its launch. The company's expanding presence is indicated by its coverage of around 867 hospitals and onboarding of 782 direct-to-patient pharmacies and hospitals, representing a 17% increase compared to the previous year. Furthermore, the favorable market conditions for U.S.-listed Chinese biotechs, marked by improved liquidity and capital formation, contribute positively to the overall outlook for Ascentage Pharma Group.

Bears say

Ascentage Pharma Group's stock outlook is negatively impacted by ongoing downward pressure from volume-based procurement programs, which have begun to affect innovative therapies and may lead to reduced revenue growth and margin erosion due to aggressive NRDL repricing cycles. The company's disappointing clinical trial results, including the failure to meet primary endpoints, raise concerns about its global growth potential and competitive positioning, particularly in the less competitive landscape of myelodysplastic syndrome. Additionally, slow adoption rates in China and the inability of their lead drug, Olverembatinib, to clinically differentiate from established therapies further hinder potential sales and revenue growth.

AAPG has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Buy based on their latest research and market trends.

According to 4 analysts, AAPG has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.